TY - JOUR
T1 - Association between cognitive trajectories and disability progression in patients with relapsing-remitting multiple sclerosis
AU - Merlo, Daniel
AU - Stankovich, Jim
AU - Bai, Claire
AU - Kalincik, Tomas
AU - Zhu, Chao
AU - Gresle, Melissa
AU - Lechner-Scott, Jeannette
AU - Kilpatrick, Trevor
AU - Barnett, Michael
AU - Taylor, Bruce
AU - Darby, David
AU - Butzkueven, Helmut
AU - Van Der Walt, Anneke
N1 - Funding Information:
Funding by Novartis Australia (unrestricted funding, grant CFTY720D2418T) with additional support from Biogen.
Funding Information:
D. Merlo, J. Stankovich, and C. Bai report no disclosures relevant to the manuscript. T. Kalincik served on scientific advisory boards for Roche, Celgene, Genzyme-Sanofi, Novartis, Merck. and Biogen and steering committee for Brain Atrophy Initiative by Genzyme; received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Genzyme-Sanofi, Teva, BioCSL, and Merck; and received research support from Biogen. C. Zhu reports and M. Gresle report no disclosures relevant to the manuscript. J. Lechner-Scott accepted travel compensation from Novartis, Biogen, and Merck. Her institution receives the honoraria for talks and advisory board commitment from Bayer Health Care, Biogen, Genzyme Sanofi, Merck, Novartis, and Teva, and she was involved in clinical trials with Biogen, Novartis, and Teva. T. Kilpatrick reports no disclosures relevant to the manuscript. M. Barnett has received institutional support for research, speaking, and/or participation in advisory boards for Biogen, Merck, Novartis, Roche, and Sanofi Genzyme and research support from the Nerve Research Foundation, University of Sydney. B. Taylor reports no disclosures relevant to the manuscript. D. Darby is consultant to uBrain, former founder and shareholder of CogState, and chief executive officer of Cerescape and received honoraria for lectures from Biogen, Novartis, and other pharma. H. Butzkueven served on scientific advisory boards for Biogen, Novartis, and Sanofi-Aventis and received conference travel support from Novartis, Biogen, and Sanofi Aventis. He serves on steering committees for trials conducted by Biogen and Novartis and received research support from Merck, Novartis, and Biogen. A. van der Walt has received travel support from and served on advisory boards for Novartis, Biogen, Merck Serono, Roche, and Teva. She receives grant support from the National Health and Medical Research Council of Australia. Go to Neurology.org/N for full disclosures.
Publisher Copyright:
Copyright © 2021 American Academy of Neurology.
PY - 2021/11/16
Y1 - 2021/11/16
N2 - Background and Objectives Longitudinal cognitive trajectories in multiple sclerosis are heterogeneous and difficult to measure. We aimed to identify discrete longitudinal reaction time trajectories in relapsingremitting multiple sclerosis using a computerized cognitive battery and to assess the association between trajectories of reaction time and disability progression. Methods All participants serially completed computerized reaction time tasks measuring psychomotor speed, visual attention, and working memory. Participants completed at least 3 testing sessions over a minimum of 180 days. Longitudinal reaction times were modeled with latent class mixed models to identify groups of individuals sharing similar latent characteristics. Optimal models were validated for consistency and baseline associations with class membership tested using multinomial logistic regression. Interclass differences in the probability of reaction time worsening and the probability of 6-month confirmed disability progression were assessed with survival analysis. Results A total of 460 people with relapsing-remitting multiple sclerosis were included in the analysis. For each task of the MSReactor battery, the optimal model comprised 3 latent classes. All MSReactor tasks could identify a group with high probability of reaction time slowing. The visual attention and working memory tasks could identify a group of participants who were 3.7 and 2.6 times more likely to experience a 6-month confirmed disability progression, respectively. Participants could be classified into predicted cognitive trajectories after just 5 tests with 64% to 89% accuracy. Discussion Latent class modeling of longitudinal cognitive data collected by a computerized battery identified patients with worsening reaction times and increased risk of disability progression. Slower baseline reaction time, age, and disability increased assignment into this trajectory. Monitoring of cognition in clinical practice with computerized tests may enable detection of cognitive change trajectories and people with relapsing-remitting multiple sclerosis at risk of disability progression.
AB - Background and Objectives Longitudinal cognitive trajectories in multiple sclerosis are heterogeneous and difficult to measure. We aimed to identify discrete longitudinal reaction time trajectories in relapsingremitting multiple sclerosis using a computerized cognitive battery and to assess the association between trajectories of reaction time and disability progression. Methods All participants serially completed computerized reaction time tasks measuring psychomotor speed, visual attention, and working memory. Participants completed at least 3 testing sessions over a minimum of 180 days. Longitudinal reaction times were modeled with latent class mixed models to identify groups of individuals sharing similar latent characteristics. Optimal models were validated for consistency and baseline associations with class membership tested using multinomial logistic regression. Interclass differences in the probability of reaction time worsening and the probability of 6-month confirmed disability progression were assessed with survival analysis. Results A total of 460 people with relapsing-remitting multiple sclerosis were included in the analysis. For each task of the MSReactor battery, the optimal model comprised 3 latent classes. All MSReactor tasks could identify a group with high probability of reaction time slowing. The visual attention and working memory tasks could identify a group of participants who were 3.7 and 2.6 times more likely to experience a 6-month confirmed disability progression, respectively. Participants could be classified into predicted cognitive trajectories after just 5 tests with 64% to 89% accuracy. Discussion Latent class modeling of longitudinal cognitive data collected by a computerized battery identified patients with worsening reaction times and increased risk of disability progression. Slower baseline reaction time, age, and disability increased assignment into this trajectory. Monitoring of cognition in clinical practice with computerized tests may enable detection of cognitive change trajectories and people with relapsing-remitting multiple sclerosis at risk of disability progression.
UR - http://www.scopus.com/inward/record.url?scp=85120641965&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000012850
DO - 10.1212/WNL.0000000000012850
M3 - Article
C2 - 34556562
AN - SCOPUS:85120641965
SN - 0028-3878
VL - 97
SP - E2020-E2031
JO - Neurology
JF - Neurology
IS - 20
ER -